This report was first published by Endpoints News. To see the original version, click here
Last April, Chinese regulators approved Belief BioMed’s gene therapy for the bleeding disorder hemophilia B, setting up a challenge to one of the priciest medicines.
The treatment marked the first hemophilia gene therapy in China to be developed and manufactured entirely by a domestic company. Belief BioMed priced it at $350,000, one-tenth the cost of a rival therapy that sells for $3.5 million in the US.
您已阅读5%（497字），剩余95%（9672字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。